Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 337–360 / 473
HN2301 delivers CD19 CAR mRNA using engineered T-cell-targeted LNPs. MagicRNA reports first-in-human SLE findings published in the New England Journal of Medicine. The older English homepage’s IND-enabling description is not used to override the later human-study disclosure.
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
Simnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
Immunofoco’s iMagic platform uses a fusogen and T-cell-targeting modules for in vivo CAR-T. It identifies CD19 IMV101 in IITs, alongside BCMA IMV102 and CLDN18.2 IMV103. Phase 3 IMC002 is an ex vivo program and does not establish in vivo Phase 3 development.
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
Oricell explicitly lists OriV508, a CD19/BCMA in vivo CAR-T program, as IIT ongoing, and OriV118 targeting GPRC5D/BCMA. The pipeline does not establish the delivery platform or OriV118’s current stage. Its ex vivo OriCAR-017 data must be kept separate.
Vivacta is a GRIT in vivo CAR-T platform spinout developing CD19 mRNA/tLNP candidate GT801. A first-in-human study is registered as NCT07205315. Its October 2026 U.S. orphan designation for AIHA is not approval or proof of efficacy; GT801 is shared with the GRIT profile.
BR101 is a BCMA/CD19 circular mRNA in vivo CAR-T program in a registered IIT for relapsed/refractory myeloma (NCT07537049). Autoimmune development and BR102/BR103 are separately described as preclinical; their stages should not be inferred from BR101.
RXIM002 uses targeted LNPs carrying CD19 CAR circular RNA. The August 2026 update reports ongoing China IIT follow-up and FDA IND clearance for autoimmune cytopenias. It also discloses a fatal serious adverse event in a participant with systemic sclerosis; causality should not be inferred.
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
GenVivo identifies GEN-310 as an in vivo CAR-T/NK program for B-cell malignancies. Its October 2025 corporate presentation classifies GEN-310 as preclinical. Clinical work on separate immunocytokine vectors should not be used to upgrade this CAR program.
Manufacturing partner uBriGene identifies Cellinfinity’s CIB-301 and CIB-350 as in vivo CAR-T programs for hematologic and solid tumors, supported by lentiviral vector manufacturing. The March 2026 announcement does not establish a registered clinical phase or human efficacy.
Jenthera discloses an in vivo autologous CAR-T reprogramming program in B-cell lymphoma using targeted ribonucleoprotein genome editing and homology-directed insertion. Website tumor-eradication statements do not establish human efficacy.
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
Immugenia discloses lentiviral in vivo CAR delivery to T/NK cells and HSCs, with promoter-restricted expression in T/NK lineages. HSC-derived replenishment differs from direct mature-T-cell engineering. The public disclosure does not establish a current CAR-T clinical phase.
An October 2026 company announcement describes an in vitro feasibility study combining FLT3 CAR mRNA with Nitto’s cell-targeted LNPs. This is an early in vivo CAR-T development effort, not human in vivo treatment. Clinical HG-CT-1 is a separate ex vivo product.
Nona supplies antibody discovery and CAR screening for Umoja’s in vivo CAR-T collaboration. The November 2025 agreement assigns subsequent product development and commercialization to Umoja. Nona is labeled an enabling partner, not a separately confirmed clinical CAR-T developer.
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
Axelyf identifies AX-004 as its proprietary in vivo CAR-T candidate for solid tumors using AXL LNP delivery. Disclosed support is from mouse and non-human-primate studies; human dosing or clinical efficacy is not inferred.
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
Mana.bio applies machine learning to LNP design and disclosed a 2026 ASGCT presentation on progress toward in vivo CAR-T. The accessible material supports delivery-platform research; a named therapeutic candidate, clinical initiation, and patient efficacy were not verified.
Coverage expands from sourced records; this database does not claim all biopharma companies.
